SCHEMBL3207769

SCHEMBL3207769

CN(C)c1ccc2sc(CO)cc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.53
APP P05067 6/20 0.41
EGFR P00533 1/20 0.37
TERT O14746 1/20 0.36
PTPN2 P17706 1/20 0.35
PSMB5 P28074 3/20 0.34
ADRB2 P07550 1/20 0.34
INSR P06213 1/20 0.34
ASIC3 Q9UHC3 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33
CA2 P00918 1/20 0.33
ALDH1A1 P00352 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
LMNA P02545 1/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
APAF1 O14727 1/20 0.33
GSR P00390 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL122572 0.77 CYP2A6 (0.58) CYP2A6PTPN2ADRB2ASIC3LOXL2
SCHEMBL9374785 0.74 CYP2A6 (0.60) CYP2A6PTPN2ASIC3LOXL2CA2
SCHEMBL16398343 0.74 CYP2A6 (0.55) CYP2A6PTPN2ADRB2ASIC3LOXL2
SCHEMBL13779418 0.73 APP (0.39) APPEGFRTERTPSMB5INSR
SCHEMBL11485426 0.73 CYP2A6 (0.58) CYP2A6PTPN2ASIC3LOXL2CA2
SCHEMBL24601455 0.73 CYP2A6 (0.58) CYP2A6APPPTPN2ADRB2ASIC3
SCHEMBL3051489 0.73 CYP2A6 (0.58) CYP2A6PTPN2ADRB2ASIC3LOXL2
SCHEMBL793711 0.73 CYP2A6 (0.58) CYP2A6PTPN2ADRB2ASIC3LOXL2
SCHEMBL31095741 0.73 CYP2A6 (0.58) CYP2A6PTPN2ADRB2ASIC3LOXL2
SCHEMBL6839989 0.72 BACE1 (0.62) CYP2A6CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683185-B2 Histone deacetylase inhibitors QUEEN MARY & WESTFIELD COLLEGE (GB) 2010-03-23 US disclosed
US-20060235231-A1 6-(4-Dimethylamino-phenylsulfanyl)-hexa-2,4-dienoic acid methyl ester; stimulating hematopoietic cells ex vivo UCL BIOMEDICA PLC (GB) 2006-10-19 US disclosed
EP-1565432-A1 HISTONE DEACETYLASE INHIBITORS QUEEN MARY & WESTFIELD COLLEGE (GB) 2005-08-24 EP disclosed
WO-2004046094-A9 HISTONE DEACETYLASE INHIBITORS QUEEN MARY & WESTFIELD COLLEGE (GB) 2005-06-23 WO disclosed
WO-2004046094-A1 HISTONE DEACETYLASE INHIBITORS QUEEN MARY & WESTFIELD COLLEGE (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235231-A1 6-(4-Dimethylamino-phenylsulfanyl)-hexa-2,4-dienoic acid methyl ester; stimulating hematopoietic cells ex vivo HDAC1, HDAC7, HDAC5 CYP2A6 1341/4885APP 4820/4885EGFR 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.